LONG BEACH, Calif. / Jan 04, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the fourth quarter and year ended December 31, 2023.
Molina Healthcare will issue its earnings release for the fourth quarter and year ended December 31, 2023, after the market closes on Wednesday, February 7, 2024, and will host a conference call and webcast to discuss the earnings release on Thursday, February 8, 2024, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 4221213. A telephonic replay of the conference call will be available through Thursday, February 15, 2024, by dialing (877) 344-7529 and entering the confirmation number, 3687293.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed health care services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.2 million members as of September 30, 2023, located across 19 states. For more information about Molina Healthcare, please visit molinahealthcare.com.
Last Trade: | US$296.88 |
Daily Change: | 3.32 1.13 |
Daily Volume: | 322,481 |
Market Cap: | US$16.980B |
November 18, 2024 October 23, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load